Utilizing AI for Quantitative Assessment of Prostate Cancer Recurrence

The Pulmonary Embolism (PE) Triage and Notification (PETN) module with RapidAI’s RapidPE platform reportedly demonstrated over 90 percent sensitivity and specificity rates for detection of central PE on computed tomography (CT), according to multicenter study findings presented at the 9th Annual Pulmonary Embolism Symposium.

For cT1 renal masses < 4 cm and renal masses < 2 cm, the PET/CT agent 89Zr-DFO-girentuximab had respective sensitivity rates of approximately 85 percent and 96.7 percent for diagnosing clear cell renal cell carcinoma, according to research recently presented at the European Association of Nuclear Medicine (EANM) 2023 Congress.

Twice-a-day consumption of reconstituted grape powder provides significant long-term benefit in preserving cerebral metabolism for people with mild cognitive decline, according to research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

The PSMA PET agent 64Cu SAR-bisPSMA detected a higher number of prostate cancer lesions and had a significantly higher SUVmax and SUVmean than 68Ga PSMA-11 PET/CT, according to initial data from a prospective multisite study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.

Featuring sector and linear arrays, the FDA-cleared Vscan Air SL ultrasound device reportedly enables cardiac and vascular assessments at the point of care.

In an analysis of patients with intraprostatic/prostate bed findings of biochemical prostate cancer recurrence, the use of 18F-DCFPyL PET/CT led to an 82.3 percent cancer detection rate in comparison to 80 percent for multiparametric MRI, according to research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.